Efavirenz, (R)-
| Code | Size | Price |
|---|
| TAR-T25363-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T25363-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T25363-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Efavirenz, (R)- is an antiviral agent and a nonnucleoside HIV-1 reverse transcriptase inhibitor.
CAS:
154801-74-8
Formula:
C14H9ClF3NO2
Molecular Weight:
315.68
Purity:
0.98
SMILES:
FC(F)(F)[C@@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1
References
1. Gleason RL Jr, Caulk AW, Seifu D, Parker I, Vidakovic B, Getenet H, Assefa G, Amogne W. Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia. PLoS One. 2015 Apr 27;10(4):e0117125. doi: 10.1371/journal.pone.0117125. eCollection 2015. PubMed PMID: 25915208; PubMed Central PMCID: PMC4411122.
2. Arpadi SM, Shiau S, Strehlau R, Patel F, Mbete N, McMahon DJ, Kaufman JJ, Coovadia A, Kuhn L, Yin MT. Efavirenz is associated with higher bone mass in South African children with HIV. AIDS. 2016 Oct 23;30(16):2459-2467. PubMed PMID: 27427876; PubMed Central PMCID: PMC5069169.
3. Imaz A, Llibre JM, Navarro J, Curto J, Clotet B, Crespo M, Ferrer E, Saumoy M, Tiraboschi JM, Murillo O, Podzamczer D. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml. Antivir Ther. 2014;19(6):569-77. doi: 10.3851/IMP2736. Epub 2014 Jan 23. PubMed PMID: 24458091.
4. Vesterbacka J, Nowak P, Barqasho B, Abdurahman S, Nystr?m J, Nilsson S, Funaoka H, Kanda T, Andersson LM, Gissl?n M, S?nnerborg A. Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy. PLoS One. 2013;8(1):e55038. doi: 10.1371/journal.pone.0055038. Epub 2013 Jan 28. PubMed PMID: 23383047; PubMed Central PMCID: PMC3557242.